Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia

1. Front Matter

   Pages i-xiv

   PDF

2. Evolving Concepts in Myelodysplastic Syndromes

   • Azra Raza

   Pages 1-24

3. In Vitro Biology of the Hematopoietic System in Myelodysplastic Syndromes

   • Hector Mayani

   Pages 25-43

4. Biology of Stem and Myeloid Progenitor Cells in Myelodysplastic Syndromes

   • Lambert F. R. Span, Theo M. de Witte

   Pages 45-63

5. Novel in Vitro Culture and Ultrastructural Techniques to Study the Biology of Myelodysplastic Syndromes (MDS)

   • Sairah Alvi, Laurie A. Lisak, Vilasini T. Shetty

   Pages 65-79

6. The Monocytic Component in Myelodysplastic Syndromes

   • Gianluigi Castoldi, Gian Matteo Rigolin

   Pages 81-92

7. Cytokines and MDS

   • Krishnan Allampallam, Vilasini T. Shetty, Azra Raza

   Pages 93-100

8. Apoptosis in MDS: A New Perspective

   • Suneel D. Mundle

   Pages 101-109

9. Molecular, Cytogenetic and Genetic Abnormalities in MDS and Secondary AML

   • Rose Ann Padua, Angela McGlynn, Hugh McGlynn

   Pages 111-157

10. Stem Cell Transplantation for Myelodysplasia

    • Hans-G. Klingemann, H. Joachim Deeg

    Pages 159-168

11. Myelodysplastic Syndromes Complicating Hematopoietic Stem Cell Transplantation

    • Athanasios B.-T. Fassas, Guido Tricot

    Pages 169-184

12. Evolution of Secondary Hematologic Disorders: PREMDS→MDS→sAML

    • Harvey D. Preisler

    Pages 185-230

13. The Impact of Biology on the Treatment of Secondary AML

    • Ivana Gojo, Judith E. Karp

    Pages 231-255

14. Special Clinical Concerns/ Problems in the Management of MDS and Sedondary Acute Myeloid Leukemias

    • Parameswaran Venugopal, Sharon Manson, Harvey D. Preisler

    Pages 257-265

15. MDS and Secondary AML : An Evolutionary Perspective

    • M. William Audeh

    Pages 267-278

16. Back Matter

    Pages 279-280

    PDF

Myelodysplastic syndromes are to the bone marrow what pneumonia is to the lungs; the response of an organ to a variety of etiologic insults like aging, toxic exposure, infections and auto-immunity. Among infectious causes alone, pneumonia could be the result of a variety of possible pathogens including bacterial, viral, tuberculous or fungal agents. Similarly, MDS cannot be treated as a single disease. Attempts to harness the inherent complexity of MDS by devising `classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics. Progress in the field will occur faster when we re-analyze this premise. Therefore, until a clearer picture of the disease emerges it is best to treat each of the MDS syndromes as a separate entity. Having no classification is better than a misleading one.
Cancer research has been notable for its periodic cycles of promise and hope, followed by defeat and disappointments. It is not that there is no solution, but that the problem has not been identified precisely. This book is our attempt to define the most crucial questions related to MDS that need to be addressed immediately through logic, analysis and rigorous experimentation. If the emerging problems appear daunting, then instead of being overwhelmed by them, we should follow the advice of the great 20th century thinker Antonio Gramsci, `pessimism of the intellect must be faced with the optimism of will'.

• aging
• antibiotics
• apoptosis
• cell
• classification
• cytokines
• hematopoietic stem cell
• hematopoietic stem cell transplantation
• leukemia
• stem cell
• stem cell transplantation
• transplantation

• MDS Center and Section of Myeloid Diseases, USA

  Azra Raza, Suneel D. Mundle

Policies and ethics